OBJECTIVE To optimize the formulations of nimodipine matrix tablet using D-optimal mixture design. METHODS Independent variables were the amounts of HPMC, sodium alginate and lactose, and drug accumulated release at 3, 6, 9 and 12 h were dependent variables. Optimal mathematical models were chosen to estimate the relationship between the dependent and the independent variables,and to delineate triangular-dimensional contour plots. With appointed drug release at 3,6,9 and 12 h as target values, overlay plot was used to predict the optimal formulation. Validation of optimal formulation was verified at last. RESULTS In optimal regression models, there are reliable quantitative relationships between three factors and four evaluation indexes. In vitro release test of five optimal checkpoint formulations indicated that there existed high approximation between their predicted and experimental values.The values of similarity factor (f2) indicated the equivalence to the release profile of the optimum formulation and zero-order release profile. CONCLUSION D-optimal mixture experimental design facilitated the optimization of nimodipine matrix formulations. Optimal models are proved to have the ability of high prognostic and feasible.
JIN Xing-hu;ZHNG Yun-hui;ZHO Zhen-yu;XIO Li;ZHNG Dn;WNG Yn.
Optimization the Formulations of Nimodipine Matrix Tablet Using D-Optimal Mixture Design [J]. Chinese Pharmaceutical Journal, 2009, 44(07): 516-520
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] HOLM R，JENSEN I H，SONNERGAARD J.Optimization of self-microemulsifying drug delivery systems (SMEDDS) using a D-optimal design and the desirability Function[J].Drug Dev Ind Pharm，2006，32(9)：1025-1032.
[2] PETROVIC A，CVETKOVIAE N，TRAJKOVICT S，et al.Mixture design evaluation of drug release from matrix tablets containing carbomer and HPMC[J].J Controlled Release，2006，116(2)：104-106.
[3] CHOPRA S，PATIL G V，MOTWANI S K.Release modulating hydrophilic matrix systems of losartan potassium：optimization of formulation using statistical experimental design.[J].Eur J Pharm Biopharm，2007，66(1)：73-82.
[4] FAN C X，LIANG W Q.An artificial neural network for multi-objective simultaneous optimization of HPMC sustained release tablet formulations[J].Chin Pharm J (中国药学杂志)，2004，39(10)：768-771.
[5] HUANG Y B，TSAI Y H，YANG W C，et al.Once-daily propranolol extended-release tablet dosage form：formulation design and in vitro/in vivo investigation[J].Eur J Pharm Biopharm，2004，58(3)：607-614.
[6] ANDERSON-COOK C M，GOLDFARD H B，BORROR C M，et al.Mixture and mixture-process variable experiments for pharmaceutical applications[J].Pharm Stat，2004，3(4)：247-260.
[7] MURA P，GRATTERI P，FAUCCI M.Compatibility studies of multicomponent tablet formulations. DSC and experimental mixture design[J].J Therm Anal Calorim，2002，68(2)：541-551.
[8] BODEA A，LEUCUTA S E.Optimization of hydrophilic matrix tablets using a D-optimal design[J]. Int J Pharm，1997，153(2)：247-255.
